The Importance of Pre-Use Integrity Testing in Sterilizing Filtration - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Importance of Pre-Use Integrity Testing in Sterilizing Filtration
Pre-use integrity testing of sterilizing-grade filters eliminates the potential adverse effects of filter loading on the integrity-test results, allowing unambiguous correlation with the integrity-test specification established during filter-validation studies.


Pharmaceutical Technology


A septically produced liquid pharmaceutical and biopharmaceutical products are usually sterilized by filtration. The filtration process must be validated to ensure that it is capable of removing all microorganisms from the product. Validation consists of challenging the filter with a suspension of Brevundimonas diminuta and analyzing the filtrate for microorganisms. The filtrate must be sterile.

Filters used in production should be equivalent to the filters used in the bacterial-challenge validation studies. Because actual production filters cannot undergo bacterial-challenge testing, integrity testing is performed to demonstrate bacterial-retention equivalence. If the integrity-test values obtained for the production filters are equivalent to those obtained for the filters successfully passing bacterial-challenge testing, then it is assumed that the filters have the same bacterial-retention properties and that the filtered pharmaceutical product is, therefore, sterile.

Integrity testing for the hydrophilic filters used in pharmaceutical production relies on the measurement of gas flow through wetted membranes. This flow can be classified as diffusive or bulk and is sometimes a combination of both. Fick's Law of Diffusion shows that diffusion of the test gas through the liquid-filled pores in the membrane is a function of the diffusion constant and the solubility of the test gas in the liquid at the test temperature, the pressure differential of the test gas across the membrane, the thickness of the liquid layer, and the area and porosity of the membrane (1). Diffusion is not directly related to pore size although, as will be shown later, there is an indirect correlation. Bulk flow occurs when the test gas flows through the nonwetted or empty pores of the membrane. Open pores occur because the filter membrane has been incompletely wetted or because the bubble point of the membrane has been exceeded. Bulk flow primarily is a function of the size and number of the open pores, the thickness of the membrane, and the pressure differential of the test gas across the membrane at the test temperature.

Gas flow through wetted membranes


Figure 1
As indicated previously, gas flow through wetted membranes is diffusive, bulk, or a combination of both. Figure 1 shows the relationship between gas flow and differential pressure for a typical membrane filter. Similarly, because it is an arithmetic function, pure bulk flow is a straight line whose slope is determined by the size and number of open pores, assuming all other variables are held constant.

The knee area of the curve is where the influence of the bubble point is manifested. Here, the largest pores of the filter become unblocked as the applied pressure overcomes the capillary forces within those pores, and bulk flow begins to increase the slope of the curve. It is also in this region that diffusive flow begins to increase because the thickness of the liquid trapped in the largest pores begins to decrease as a result of the increasing pressure differential. Therefore, within the knee area of the curve a complex relationship exists between diffusive and bulk flow, both influenced by the pore structure and pore-size distribution.

Filter validation


Figure 2
Validating the bacterial-retention capabilities of sterilizing-grade filters involves challenging the filters with a suspension of B. diminuta (ATCC 19146) at a level of at least 1 × 107 CFU/cm2 of filter area, resulting in a sterile filtrate. Specific details and options may be found in "PDA Technical Report No. 26" (2). The integrity-test values of the filters used in the bacterial challenge studies must be known to form the basis for ensuring the filters used in production have equivalent bacterial-retention capabilities. In addition to the integrity-test values, the manufacturing processes and quality-assurance systems of the filter manufacturer must be adequate to ensure consistency of the filters within and between each manufactured lot with respect to nominal pore size, pore-size distribution, and membrane thickness and area.


ADVERTISEMENT

RELATED CONTENT
The Role of Glasses in Aseptic Production: A Detail Often Ignored
Risk-Management Assessment of Visible-Residue Limits in Cleaning Validation
The Effect of Carrier Material on the Measured Resistance of Spores
The Importance of Pre-Use Integrity Testing in Sterilizing Filtration
Radiation Sterilization of Parenterals
blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
25%
To select processes for both new and legacy products
20%
Do not use QbD
23%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here